Neutral
Franklin Resources Inc. significantly reduced its stake in Amgen Inc. by 17.7% in the fourth quarter, yet still holds 2.18 million shares valued at ab...
Neutral
Amgen's stock has outperformed the S&P 500 recently, driven by investor focus on its obesity drug, MariTide, as key blockbusters like Prolia and XGEVA...
Bullish
O Shaughnessy Asset Management LLC increased its stake in Amgen Inc. (NASDAQ:AMGN) by 25.7% in the fourth quarter, acquiring an additional 27,035 shar...
Bullish
Hilton Head Capital Partners LLC initiated a new position in Amgen Inc. during the fourth quarter, acquiring 3,798 shares valued at approximately $1.2...
Bullish
Amgen is developing MariTide, an experimental monthly GLP-1 injection, which aims to improve convenience and patient adherence compared to weekly dose...
Bullish
Amgen is developing MariTide, an experimental GLP-1 drug, which aims to improve convenience and adherence with monthly injections instead of weekly on...
Neutral
Capital International Ltd. CA reduced its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 51.2% during the 4th quarter, according to the company...
Bullish
Amgen recently received European marketing authorization for IMDYLLTRA (tarlatamab) for extensive-stage small cell lung cancer and presented positive ...
Bullish
Vestcor Inc. significantly reduced its stake in Amgen Inc. by selling 10,133 shares, leaving them with 19,353 shares valued at approximately $6.33 mil...
Neutral
Vise Technologies Inc. significantly increased its stake in Amgen Inc. (NASDAQ:AMGN) by 66.4% in the fourth quarter, bringing its total holdings to 19...
Neutral
J.W. Cole Advisors Inc. reduced its stake in Amgen Inc. by 27.6% in the Q4, selling 6,407 shares and now owning 16,789 shares valued at $5.495 million...
Goldman Sachs has reaffirmed its Buy rating for Amgen (AMGN.US) but has adjusted its target price downwards to $389. This indicates a continued positi...
Amgen's stock has seen a 24% gain over the past year, prompting an assessment of its current valuation. Simply Wall St's model indicates that Amgen (A...
Bullish
Harvest Fund Management Co. Ltd increased its stake in Amgen Inc. by 28.3% in the fourth quarter, reaching a total holding of 48,412 shares valued at ...
Neutral
Amgen (NASDAQ: AMGN) will present new data at EULAR 2026 for its rare autoimmune and inflammatory disease drugs, UPLIZNA and TAVNEOS. UPLIZNA showed s...
Bullish
Natixis Advisors LLC increased its stake in Amgen Inc. to 346,039 shares, valued at $113.26 million, marking a 1.5% rise in the fourth quarter. Instit...
The article discusses the evolving approach to obesity care, moving from perceiving it as a willpower issue to recognizing it as a chronic condition. ...
Neutral
Amgen has received EU approval for its drug Imdylltra (tarlatamab) to treat adults with extensive-stage small cell lung cancer (SCLC) after progressio...
Bullish
The ANCA Vasculitis market is projected to grow from approximately USD 1.8 billion in 2025 to nearly USD 3.8 billion by 2036, driven by increased prev...
Amgen sponsored a cardiovascular and metabolic health screening event at the Congo Square Rhythms Festival in New Orleans to address the city's high r...